Login
Companies $WGS
$50.50 -$0.52 (1.02%) After hours
GeneDx Holdings Corp. logo

GeneDx Holdings Corp.

sema4.com

What Do They Do?

Provides genetic and genomic diagnostic tests and interpretation services to clinicians, hospitals, and biopharma companies.

How Do They Make Money?

Most revenue comes from diagnostic tests: insurers, patients and institutions pay for a test when its results are delivered; institutions pay contracted rates. Collaboration agreements can also include nonrefundable and milestone payments.

revenue
SegmentShareRevenue
Patients with third-party insurance
Sold outright

81%
FY2022: 74%
Institutional customers
Sold outright

16%
FY2022: 20%
Self-pay patients
Sold outright
0.3%
FY2022: 3.2%
Other revenue
2.5%
FY2022: 3.1%

Who Are Their Customers?

GeneDx sells diagnostic tests through its direct sales team and laboratory distribution partners; buyers include healthcare professionals ordering for patients and institutions such as hospitals, clinics, state governments and reference labs. Fabric also serves clinical laboratories and research institutions with software and interpretation services.

Do Revenues Turn Into Profits?

Not on paper. It lost $21M in FY2025, but brought in more cash than it spent: $14.3M of free cash flow.

Operating income, FY2025
−3% of revenue
▲ +44% (Loss) vs FY2024 (−$23.2M, −8%)
Net income, FY2025
−5% of revenue
▲ +60% (Loss) vs FY2024 (−$52.3M, −17%)
Free cash flow, FY2025
3% of revenue
▲ Turned profitable vs FY2024 (−$34M, −11%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +5%
vs $116.7M in Q3 FY2025
Net income
▼ −61% (Loss)
vs −$7.6M in Q3 FY2025
Patients with third-party insurance share of revenue vs 81.4% in Q3 FY2025
  • Nov 9, 2026 Updated its 2026 financial guidance Revenue guidance remained $475 to $490 million; adjusted net income guidance changed to approximately $12 million.

Growing. Revenue grew 2.0x in 4 years, from $212.2M in FY2021 to $427.5M in FY2025, about 19% a year.

Fabric software and interpretation The older report described exome and genome interpretation and Centrellis platform services; the latest adds Fabric software and interpretation for rare disease, hereditary risk and cancer testing.

Broader pediatric testing focus The older report emphasized NICUs and pediatric developmental disorders; the latest also targets general pediatricians, other pediatric specialists and late-stage prenatal testing.

Revenue over time
Patients with third-party insurance Institutional customers Self-pay patients Other revenue
$500M$250M$0

Who Do They Compete With?

Competes with Illumina, Baylor Genetics, Tempus, Ambry Genetics, Variantyx, and Rady Children’s Hospital

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support